Pfizer reports phase 2 data for 25-valent pneumococcal vaccine

Markets Investing.com By Investing.com 24 Oct 2026 15:24 1 min read
Pfizer reports phase 2 data for 25-valent pneumococcal vaccine

Covered in this story

Analyst targets on Pfizer

Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.

Call it yourself

No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Pfizer →

Dalsna Finance is currently tracking 51 stories mentioning Pfizer, the earliest published 3 Sept 2026.

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.